Eribulin

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020

Tokyo, September 18, 2020: Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative…

4 years ago

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

New Delhi, May 17, 2020: Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house…

5 years ago

EISAI INDIA AND MYLAN ENTER INTO CO-EXCLUSIVE MARKETING AGREEMENTTO COMMERCILIZE TECERIS® THE SECOND ERIBULIN BRAND IN INDIA

TECERIS® aimed at expanding access to metastatic breast cancer patients in India Vishakhapatnam, September 29, 2019: Eisai Pharmaceuticals India Pvt.…

5 years ago

Eisai’s Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India

Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris Tokyo, September 21, 2019: …

5 years ago